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Abstract: The Women’s Health Initiative found that combination estrogen and progesterone hormone replacement therapy 
increases breast cancer and cardiovascular disease risk, which compelled many women to seek herbal alternatives such as 
black cohosh extract (BCE) to relieve their menopausal symptoms. While several clinical trials document the efﬁ  cacy of 
BCE in alleviating menopausal symptoms, preclinical studies to determine how BCE works have yielded conﬂ  icting results. 
Part of this is because there is not a universally accepted method to standardize the dose of black cohosh triterpenes, the 
presumed active ingredients in the extract. Although the mechanism by which BCE relieves symptoms is unknown, sev-
eral hypotheses have been proposed: it acts 1) as a selective estrogen receptor modulator, 2) through serotonergic pathways, 
3) as an antioxidant, or 4) on inﬂ  ammatory pathways. We found that while the most prominent triterpene in BCE, 23-epi-
26-deoxyactein, suppresses cytokine-induced nitric oxide production in brain microglial cells, the whole BCE extract actu-
ally enhanced this pathway. A variety of activities have been reported for black cohosh and its compounds, but the absorp-
tion and tissue distribution of these compounds is unknown. 
Keywords: Black cohosh, botanical, complementary and alternative medicine, estrogen, inﬂ  ammatory, nitric oxide
Abbreviations: BCE, black cohosh extract; SSRI, selective serotonin reuptake inhibitor; CNS, central nervous system; ER, 
estrogen receptor; OPG, osteoprotegerin; SERM, selective estrogen receptor modulator; ROS, reactive oxygen species; 
LPS, lipopolysaccharide; IFNγ, interferon γ; NO, nitric oxide; NOS, nitric oxide synthase.
Introduction
Black cohosh (Actaea racemosa, formerly Cimicifuga racemosa) is an herb used by menopausal women 
to alleviate hot ﬂ  ashes and other symptoms of hormone withdrawal. Unlike other herbal medicines used 
for this purpose, extracts of black cohosh (BCE) have been demonstrated effective for up to three months 
in most clinical trials. However, the mechanism by which BCE relieves symptoms is unclear. The alle-
viation of menopausal symptoms by BCE suggests an estrogenic mechanism, but menopausal symptoms 
can also be alleviated by selective serotonin reuptake inhibitors (SSRIs), suggesting that BCE may work 
through a serotonergic mechanism. Many menopausal symptoms—hot ﬂ  ashes, mood swings and anxiety, 
insomnia—are mediated through the central nervous system (CNS) and may be alleviated through a 
variety of mechanisms. It is possible that BCE can act via multiple tissue-dependent mechanisms, 
including estrogenic (or antiestrogenic), serotonergic, antioxidative, and inﬂ  ammatory or antiinﬂ  am-
matory. Herein we review the biological activity of black cohosh, including previously unpublished 
data supporting a novel mechanism of black cohosh action.
Standardization of BCE
Like many botanicals, the study of BCE is complicated by the lack of standardization of the extract 
to one or more active components. Indeed, in the case of BCE it is unclear what the active ingre-
dients are. Moreover, most of the research on efficacy has been conducted on the whole extract 
and not individual components present in the extract, so it is not known with certainty which 
components are essential for menopausal symptom relief. Initial reports suggesting estrogenic 
activity identified formononetin (Jarry et al. 1985), a phytoestrogen found in red clover, as a 
component of BCE, but later reports failed to find this compound (Struck et al. 1997, Kennelly 
et al. 2002, Consumer Labs, 2005). Although the active BCE component(s) responsible for alleviation 22
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of hot flashes are unknown, a number of triter-
penes in BCE have activity individually 
(Einbond et al. 2004, Burdette et al. 2002, Loser 
et al. 2000, Kruse et al. 1999, Watanabe et al. 
2002), and many BCE preparations are standard-
ized to one or more of the 20 present in BCE 
(Chen et al. 2002). Routine measurements of all 
of these compounds are not practical, both due 
to cost and to the very low levels present for 
some of the triterpenes. 2-hexylcyclopropaneoc-
tanoic acid has been suggested as a compound 
unique to BCE and is thus useful for species 
verification (Panossian et al. 2004). 23-epi-26-
deoxyactein (formerly 27-deoxyactein), cimirac-
emoside A, actein (S) and actein (R) are 
commercially available for quality control 
and are the triterpenes most often used for 
standardization.
The most commonly studied BCEs in clinical 
trials are Remifemin
® and Menofem/Klimadynon
®. 
Remifemin
® has changed formulation from a 60% 
ethanol extract to a 40% isopropanol extract, and 
the extract preparation is not consistently reported 
in trials (Ofﬁ  ce of Dietary Supplements, 2002). A 
Consumer Labs report found that nine black cohosh 
products and seven combinations of black cohosh 
with soy or red clover contained expected concen-
trations of triterpenes (2.5% or label claim) 
(Consumer Labs, 2005), while a recent study found 
variability in triterpene glycosides and other 
constituents among 11 BCE products (Jiang et al. 
2006). Variable study outcomes may be due in part 
to inconsistent triterpene concentrations present in 
the various preparations used.
Estrogenic activity of BCE
Many botanicals have been studied for estrogenic 
activity. Soy, red clover, hops, and other botanicals 
contain phytoestrogens, the best characterized 
being the soy isoﬂ  avones genistein and daidzein. 
The use of black cohosh by menopausal women 
makes the question of estrogenic activity particu-
larly relevant. Table 1 summarizes the ﬁ  ndings of 
whether BCE has estrogenic properties. Similar 
to estrogen, BCE alleviates hot ﬂ  ashes in humans, 
reduces depression in a mouse model, and may 
protect against bone loss in rats and humans 
(Blumenthal, 2003, Winterhoff et al. 2003, 
Seidlova-Wuttke et al. 2003b, Wuttke et al. 2003). 
However, molecular and physiological studies to 
determine if BCE has estrogen activity have 
yielded conﬂ  icting results. An early study indi-
cated that BCE bound to estrogen receptors (Jarry 
et al. 1985), while later studies found that it did 
not (Liu et al. 2001, Onorato and Henion, 2001). 
The ﬁ  rst study used uterine cytosol, and the later 
studies used recombinant estrogen receptors (ER) 
α and β. A third study found that BCE competed 
with estradiol for binding to ERs in uterine cytosol 
but not to recombinant ERs, conﬁ  rming the ﬁ  rst 
two seemingly conﬂ  icting reports (Jarry et al. 
1995). BCE does not induce transcription in 
estrogen response element reporter assays in yeast 
(Oerter Klein et al. 2003, Beck et al. 2003), or 
induce estrogen responsive genes in mammalian 
endometrial or breast cells, or trout liver cells (Liu 
et al. 2001, Bennetau-Pelissero et al. 2004). BCE 
does not induce the proliferation (i.e. not estro-
genic) of hormone dependent or independent 
breast or prostate cancer cell lines, but does inhibit 
proliferation (antiestrogenic) through the induc-
tion of apoptosis (Dixon-Shanies and Shaikh, 
1999, Amato et al. 2002, Zierau et al. 2002, Lupu 
et al. 2003, Bodinet and Freudenstein, 2004, 
Hostanska et al. 2004a, Jarry et al. 2005, Bodinet 
and Freudenstein, 2002, Hostanska et al. 2004b, 
Hostanska et al. 2005). However, like estrogen, 
BCE induces osteoprotegerin (OPG, a bone 
marker), progesterone receptor, and ERα in human 
osteoblast cells, and BCE upregulation of OPG is 
inhibited by the estrogen receptor antagonist ICI 
182,780, implying an estrogenic mechanism 
(Viereck et al. 2005). 
In animals, BCE increases neither uterine 
weight nor vaginal cell corniﬁ  cation (Einer-Jensen 
et al. 1996, Liske et al. 2002, Burdette et al. 2003), 
does not change serum estradiol, testosterone, FSH, 
prolactin or SHBG (Liske et al. 2002, Zhang et al. 
2003), or affect transcription of uterine estrogen 
responsive genes (Kretzschmar et al. 2005). 
Similar to estrogen, three day BCE treatment 
reduced serum LH in ovariectomized rats, although 
14 day treatment did not (Jarry and Harnischfeger, 
1985). The most consistent evidence of an estro-
genic effect of BCE is on the bone (Seidlova-
Wuttke et al. 2005, Seidlova-Wuttke et al. 2003a, 
Seidlova-Wuttke et al. 2003b, Nisslein and 
Freudenstein, 2003a, Viereck et al. 2005). 
Human data are less consistent, and no report 
has evaluated breast speciﬁ  c estrogenic effects. 
Early reports suggested an estrogenic effect of BCE 
(varying preparations and doses) on vaginal 
cytology and serum hormones. Indices of estrogenic 23
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activity in vaginal cells increased after 4 and 12 
weeks of BCE (Warnecke, 1985). Twelve weeks of 
BCE induced vaginal epithelial proliferation (Stoll, 
1987). In another study, 12 weeks of BCE did not 
change endometrial thickness, but slightly increased 
the number of superﬁ  cial vaginal cells (Wuttke et 
al. 2003). In one study, serum LH was reduced by 
BCE (Duker et al. 1991), while others failed to 
identify estrogenic effects of BCE in humans, with 
no effect on circulating LH, FSH, sex hormone 
binding globulin, estradiol, or prolactin concentra-
tions, or changes in vaginal cytology (Liske et al. 
2002) (Lehmann-Willenbrock and Riedel, 1988) 
(Nappi et al. 2005). These reports of BCE estrogenic 
activity are consistent with the effects of a selective 
estrogen receptor modulator (SERM), which acts 
as an estrogen agonist in some tissues, and as an 
estrogen antagonist in others. The ideal SERM is 
one which acts as an estrogen on bone and brain, 
but does not act as an estrogen in the breast and 
uterus. BCE may contain compounds which ﬁ  t the 
criteria of a SERM.
Serotonergic activity of BCE 
The lack of estrogenic activity in the uterus 
in vivo and breast in vitro does not rule out the 
possibility that BCE alleviates hot flashes by 
acting as an estrogen in the brain. Alternatively, 
BCE may alleviate hot flashes by acting on 
neurotransmitter systems. Selective serotonin 
reuptake inhibitors (SSRIs) are effective in 
relieving hot flashes. The SSRIs, while effective 
in up to 65% of women with hot flashes (Hoda 
et al. 2003), have side effects which lead many 
women to stop taking them. While BCE does 
not inhibit the serotonin transporter, it binds 
eight serotonin receptor subtypes, acting most 
strongly on serotonin receptors 5-HT7 and 5-
HT1A as a mixed competitive ligand, with partial 
agonist activity on 5-HT7 (Burdette et al. 2003). 
Both 5-HT7 and 5-HT1A are found in the hypo-
thalamus and are involved in thermoregulation 
(Hedlund et al. 2003, Maswood et al. 1995). In 
serotonergic neurons of the thermoregulatory 
hypothalamus, 5-HT1A interacts with the 
serotonin transporter to modulate serotonin 
reuptake (Lin et al. 1998). Estrogen binding to 
its receptor interacts with G-protein coupled 
serotonin receptors, in particular 5-HT1A (Mize 
et al. 2003). Thus, thermoregulation can be 
influenced by estrogen, SSRIs, and 5-HT1A and 
5-HT7 ligands via interactions between recep-
tors and transporters.
Table 1. Estrogenic activity of black cohosh.
 Estrogenic  Not  estrogenic  Antiestrogenic
Serum hormones  2 studies
1, Single dose  3 studies
3, 4, 5  
 BCE
2  
Uterine or vaginal tissue    7 studies
2, 3, 6, 7, 8, 9, 10 
ER binding (cytosol)  3 studies
1, 2, 11, 12  
ER binding (recombinant)    3 studies
12, 13, 14 
ERE-reporter   5  studies
7, 15, 16, 17, 18 High  dose
15
Stimulate ER   High dose
19 7  studies
2, 3, 5, 10, 13, 17, 20, 21 
responsive genes
In vivo tumor growth    2 studies
3, 22 1  study
23
In vitro cancer cell   BCE compound   2 studies
7, 17  7 studies
15, 25, 26, 27, 28, 
29, 30
growth fukinolic  acid
24
Bone markers  4 studies
2,9, 20,   1 study
31 
  antagonized by ICI 
 182780
21
Bone density  3 studies
2, 23, 31  
In general, estrogens induce a decrease in LH or FSH, increase uterine weight and vaginal cytology, compete estradiol binding to uterine 
cytosol or recombinant ER, stimulate ERE-reporter assays, ER responsive genes, promote estrogen responsive tumor growth in vivo and 
in vitro, increase or decrease bone formation or resorptive markers, and increase bone density. 
1(Duker et al. 1991), 
2(Seidlova-Wuttke et al. 
2003a), 
3(Freudenstein et al. 2002), 
4(Liske et al. 2002), 
5(Zhang et al. 2003), 
6(Einer-Jensen et al. 1996), 
7(Amato et al. 2002), 
8(Burdette 
et al. 2003, Burdette et al. 2002), 
9(Wuttke et al. 2003), 
10(Kretzschmar et al. 2005), 
11(Jarry et al. 1985), 
12(Jarry et al. 1995), 
13(Liu et al. 
2001), 
14(Onorato and Henion, 2001),
 15(Zierau et al. 2002), 
16(Beck et al. 2003), 
17(Lupu et al. 2003), 
18(Oerter Klein et al. 2003), 
19(Wober 
et al. 2003), 
20(Bennetau-Pelissero et al. 2004), 
21(Viereck et al. 2005), 
22(Nisslein and Freudenstein, 2004), 
23(Nisslein and Freudenstein, 
2003b), 
24(Kruse et al. 1999), 
25(Dixon-Shanies and Shaikh, 1999), 
26(Bodinet and Freudenstein, 2002), 
27(Bodinet and Freudenstein, 2004), 
28(Hostanska et al. 2004b), 
29(Hostanska et al. 2004a), 
30(Jarry et al. 2005), 
31(Seidlova-Wuttke et al. 2005).24
Ruhlen et al
Integrative Medicine Insights 2008:3
Antioxidant, anti-allergic and anti-
inﬂ  ammatory properties of BCE 
Increased oxidative stress and stimulation of 
inﬂ  ammatory pathways play an important role in 
the progression of many neurodegenerative 
diseases, including Alzheimer’s disease and stroke 
(Gonzalez-Scarano and Baltuch, 1999). BCE has 
been used in Korean folk medicine to treat pain 
and inﬂ  ammation. A study by Kim et al. (Kim et al. 
2004) tested the potential effects of BCE on the 
allergic response in mast cells. Oral administration 
of BCE to Sprague-Dawley rats signiﬁ  cantly inhib-
ited the anti-IgE-induced passive cutaneous 
anaphylaxis reaction in a dose-dependant fashion. 
In addition, BCE inhibited mRNA of cytokines 
(IL-4, IL-5 and TNF-alpha) induced by the inﬂ  am-
matory agents PMA and A23187 in HMC-1 human 
leukemia mast cells (Kim et al. 2004). 
It is unclear if BCE has antioxidant properties. 
While a study using the Japanese ﬁ  sh Oryzias 
latipes did not identify antioxidant effects of BCE 
and its components (Zhang et al. 2003), another 
study found that BCE and individual components 
of BCE had antioxidant properties in vitro, 
suggesting that BCE can protect against DNA 
damage caused by reactive oxygen species (ROS) 
(Burdette et al. 2002).
Biological activity of BCE compounds
Triterpene glycosides and aromatic acids are the 
main classes of BCE compounds (Chen et al. 
2002). Triterpenes, a large and structurally diverse 
family of chemicals, are found in many plants and 
in some animals (Xu et al. 2004). Triterpene glyco-
side conjugates accumulate in plants and form 
saponins (Jenner et al. 2005). Various triterpenes 
and saponins have been reported to be anti-cancer, 
anti-inﬂ  ammatory, and promote or induce apop-
tosis (Einbond et al. 2004, Jenner et al. 2005). BCE 
triterpenes have a ﬁ  ve-ring structure similar to the 
four-ring structure of steroids (Fig. 1). 23-epi-26-
deoxyactein is the major triterpene constituent of 
BCE and is commonly used for standardization 
(Chen et al. 2002).
Two major BCE fractions containing triterpene 
glycosides or aromatic acids inhibited MCF-7 cell 
proliferation and induced apoptosis, with the 
aromatic acids being more potent (Hostanska et al. 
2004b). The triterpene cimiracemoside G was 
cytotoxic to human oral squamous cell carcinoma 
but not normal human gingival fibroblasts, 
suggesting a cancer-speciﬁ  c activity (Watanabe 
et al. 2002). The triterpenes actein, 23-epi-
26-deoxyactein, cimifugoside, and cimiracemoside 
A inhibited MCF-7 cell proliferation, and actein 
was shown to induce cell cycle arrest at G1 and 
inhibit cell cycle proteins cyclin D1 and cdk4 
(Einbond et al. 2004). These studies suggest that 
individual components of BCE may have speciﬁ  c 
effects on cell metabolism, probably depending on 
the type and environment of the cells.
Aromatic acids isolated by biofractionation 
from BCE which offer protection against 
menadione-induced DNA damage in S30 breast 
cancer cells included methyl caffeate, caffeic acid, 
ferulic acid, cimiracemate A, cimiracemate B, and 
fukinolic acid (Burdette et al. 2002). Aromatic 
acids caffeic acid, fukinolic acid, and cimicifugic 
acids A, B, E and F inhibited neutrophil elastase, 
an enzyme which is elevated in plasma during 
active inﬂ  ammation (Loser et al. 2000). While BCE 
and triterpenes present in BCE inhibit MCF-7 cell 
proliferation, fukinolic acid increased proliferation 
(Kruse et al. 1999). 
BCE and neuroinﬂ  ammation
Microglial cells are CNS macrophages activated 
by exposure to lipopolysaccharide (LPS), inter-
feron gamma (IFNγ), and other factors (Minghetti 
and Levi, 1998, Banati et al. 1993). Activated 
microglia display altered morphology and secrete 
pro-inﬂ  ammatory and cytotoxic factors including 
nitric oxide (NO), prostaglandins, and ROS. 
Microglial inflammatory factors may protect 
tissues from infection, but also induce neurode-
generation.
While the constitutive production of low 
concentrations of NO by endothelial nitric oxide 
synthase (eNOS) or neuronal NOS (nNOS) is 
necessary to maintain physiologic functions, 
excess production of NO (100–1000 times more) 
by inducible NOS (iNOS) is harmful (Kuo and 
Abe, 1995). NO reacts with superoxide to form 
peroxynitrite anions, which in turn decompose to 
hydroxyl free radicals and nitrogen dioxide 
(Beckman et al. 1990). These compounds can 
target proteins and nucleic acid and inhibit function 
by forming nitrosyl derivatives. Excess NO 
production has been linked with cell death in 
neurodegenerative diseases and other brain injuries 
(Dawson and Snyder, 1994, Moncada and Higgs, 
1993).25
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The majority of mechanistic information about 
black cohosh concerns whether or not it is estro-
genic. Because hot ﬂ  ashes originate in the CNS, 
black cohosh effects may bypass or indirectly 
interact with estrogenic systems. It has been 
suggested that estrogen effects on the CNS involve 
the NO pathway (Lopez-Jaramillo and Teran, 
1999), and NO controls release of anterior pituitary 
hormones (McCann et al. 1998). The activation of 
iNOS in stress-induced temperature increase 
(Soszynski, 2006) suggests a possible non-
estrogenic thermoregulatory mechanism for black 
cohosh. In this study, we examined the effect of 
black cohosh and two of its triterpene glycosides, 
23-epi-26-deoxyactein and cimiracemoside A, on 
the induction of NO in murine BV-2 microglial 
cells by the bacteria endotoxin LPS and by IFNγ. 
Our previous studies demonstrated that LPS and 
IFNγ can induce iNOS through different signaling 
pathways in these cells (Shen et al. 2005). 
Methods
Materials
The BCE preparation CimiPure
® containing 2.5% 
triterpene glycosides was obtained from PureWorld 
(South Hackensack, NJ), while 23-epi-26-
deoxyactein was purchased from Chromadex 
(Santa  Ana, CA). Black cohosh roots and rhizomes 
from the University of Missouri Botanical Center 
were powdered. All test chemicals were dissolved 
in dimethylsulfoxide prior to use.
Cells
Immortalized BV-2 murine microglia cells were 
maintained in DMEM with 5% FBS, 1% penicillin/
streptomycin and 1% fungizone. RAW 264.7 
murine macrophage cells were maintained in 
DMEM with 10% FBS, 1% penicillin/streptomycin 
and 1% fungizone. The cells were grown to 90% 
Figure 1. 23-epi-26-deoxyactein (A) and 17β-estradiol (B).26
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conﬂ  uence in 12- or 24- well plates. BV-2 cells 
were serum starved for 4 hours before overnight 
treatment with IFNγ (R&D Systems, Minneapolis, 
MN or Chemicon, Temecula, CA) or LPS (Sigma, 
St. Louis, MO). RAW 264.7 cells were treated 
overnight with IFNγ (R&D Systems, Minneapolis, 
MN or Chemicon, Temecula, CA) or LPS, and 
were not serum starved. We conducted a dose-
response to determine the optimal concentrations 
of cytokines to induce at least 20 μM NO produc-
tion, which is approximately 50% of maximal 
stimulation. Cells were pretreated for 30 minutes 
with BCE or 23-epi-26-deoxyactein prior to 
exposure to IFNγ or LPS. NO was determined by 
measuring levels of nitrite in the medium using the 
Greiss reaction. 
RT-PCR
RNA was isolated using an RNEasy Mini Kit 
(Qiagen, Valencia, CA). Total RNA was quantiﬁ  ed 
by spectrophotometer. Primer sequences were 5’-
GACAAGCTGCATGTGACATC-3’ and 5’-
GCTGGTAGGTTCCTGTTGTT -3’ for iNOS and 
5’-TGGAGAAGAGCTATGAGCTGCCTG-3’ and 
5’-GTGCCACCAGACAGCACTGTGTTG-3’ for 
β-actin. Superscript III One Step (Invitrogen, 
Carlsbad, CA) was used for RT-PCR with 16 μg 
total RNA. iNOS was ampliﬁ  ed 25 cycles and β-
actin for 30 cycles. 
Statistics
Data were analyzed by ANOVA considering the effect 
of treatment in the model using the Statistical Analysis 
System (SAS). If the main effect was signiﬁ  cant, least 
squared difference was used for means separation. A 
P-value of less than 0.05 was considered statistically 
signiﬁ  cant. All data are expressed as mean ±SE from 
at least three experiments.
Results
Typically, unstimulated BV-2 cells produced less 
than 5 μM NO. BV-2 cells stimulated for 18 hours 
with IFNγ produced 38 ± 7 μM NO. BV-2 cells 
stimulated for 18 hours with LPS produced 
29 ± 6 μM NO. 30 μg/ml 23-epi-26-deoxyactein 
had no effect on NO production, but inhibited 
IFNγ-induced NO production in a dose dependent 
fashion up to 14%, with a slight increase observed 
at the lower doses (0.3 μg/ml) of 23-epi-26 deoxy-
actein (Fig. 2A). 30 μg/ml 23-epi-26-deoxyactein 
slightly stimulated LPS-induced NO production 
(Fig. 2A). 13 μg/ml cimiracemoside A slightly 
decreased NO production after induction by IFNγ 
(Fig. 2B).
Addition of 130 μg/ml BCE did not alter NO 
production in BV-2 cells, but increased NO produc-
tion in IFNγ-stimulated cells in a dose-dependent 
fashion from 0.13 to 130 μg/ml BCE. Speciﬁ  cally, 
addition of 130 μg/ml BCE increased NO production 
by 97 ± 30% over IFNγ alone (Fig. 3A). BCE (13 
and 130 μg/ml) slightly increased NO production in 
LPS-stimulated cells. To determine if this effect was 
consistent across different sources of black cohosh, 
black cohosh harvested from the MU Botanical 
Center was obtained. This second BCE source (13 
to 130 μg/ml) also induced NO production in a dose 
dependent fashion, with 54 ± 4% increase at 130 
μg/ml over IFNγ alone (Fig. 3B). 
The effects of BCE and 23-epi-26-deoxyactein 
on NO production were also tested in RAW 264.7 
cells. BCE stimulated IFNγ-induced NO produc-
tion an additional 131 ± 26% over IFNγ alone in 
a dose dependent fashion from 0.13 to 130 μg/ml, 
while 30 μg/ml 23-epi-26-deoxyactein suppressed 
NO production by up to 23 ± 7%, with a slight 
increase observed at the lower doses of 0.3 μg/ml 
(Fig. 4). 
iNOS mRNA in BV2 cells was increased relative 
to β-actin control by 130 μg/ml BCE or IFNγ, and 
a further increase was observed with BCE and IFNγ 
combined (Fig. 5). 23-epi-26-deoxyactein (30 μg/
ml) did not have an observable effect on iNOS 
mRNA in IFNγ-stimulated or unstimulated cells.
Discussion
We identified, for the first time, biological 
activity of both the whole extract and the most 
prominent triterpene in BCE, 23-epi-26-
deoxyactein, in conjunction with the induction 
of NO production in microglial cells and macro-
phages. In general, neither BCE nor 23-epi-26-
deoxyactein exerted effects on LPS-induced NO 
production in these cells. However, while 
23-epi-26-deoxyactein decreased IFNγ-induced 
iNOS mRNA and NO production, BCE had the 
opposite effect. This effect was consistent in 
both BV-2 microglia and RAW 264.7 macro-
phages. The lack of effect of BCE on the LPS 
pathway is in line with the notion that this 
product would not be effective in the treatment 
of inflammatory diseases. The opposing effect 27
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of BCE and 23-epi-26-deoxyactein on IFNγ-induced 
NO production suggests that components 
present in BCE other than 23-epi-26-deoxyactein 
may be responsible for the elicited effects. 
Synthetic triterpenes tested in a similar system 
had the same effect as 23-epi-26-deoxyactein, 
suppressing iNOS expression and NO production 
(Suh et al. 1998). The specificity of these 
compounds on the IFNγ pathway is intriguing 
since immune cell IFNγ is an important innate 
factor for the body’s immune defense system 
(Owens et al. 2005). Thus, the ability of BCE 
to enhance NO production under suboptimal 
levels of IFNγ may represent a new mechanism 
of action of BCE in modulating the immune 
defense system. Obviously, more studies are 
Figure 2.  NO production from cytokine-induced BV-2 cells pretreated with A) 23-epi-26-deoxyactein (Actein) or B) cimiracemoside-A (CimA). 
Data are expressed as mean % of cytokine-treated control ± SE. *P < 0.05 vs cytokine control.28
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needed to explore the physiological significance 
of the observations resulting from this study.
While constitutive NOS (eNOS and nNOS) 
production is regulated post-transcriptionally, 
iNOS synthesis is primarily regulated transcrip-
tionally (Nathan and Xie, 1994). BCE alone was 
able to slightly upregulate iNOS activity, but its 
effects were most pronounced in conjunction with 
suboptimal levels of IFNγ. Inﬂ  ammatory systems 
may play a role in the mediation of hot ﬂ  ashes. It 
is unknown whether the pro-inﬂ  ammatory effects 
of BCE or the anti-inﬂ  ammatory effects of select 
BCE-compounds such as 23-epi-26-deoxyactein 
impact thermoregulation and thus hot ﬂ  ashes. 
It is clear that BCE acts through a variety of 
biological pathways. Our evidence supports 
mechanisms involving inﬂ  ammatory, rather than 
estrogenic, pathways. The role of specific 
Figure 3. NO production from cytokine-induced BV-2 cells pretreated with black cohosh from PureWorld (A), or MU Botanical Center (B). 
Data are expressed as mean % of cytokine-treated control ± SE. *P < 0.05 vs cytokine control.29
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chemicals or classes of chemicals, i.e. triter-
penes, should be examined in these systems. To 
determine physiological relevance it will be 
necessary to understand the pharmacokinetics 
of BCE: how it is absorbed, metabolized, tissue 
distribution, and clearance. In particular, since 
many of the post-menopausal symptoms are 
thought to arise from the CNS, more studies are 
needed to find out if specific BCE components 
can cross the blood-brain barrier and exert 
effects to regulate the CNS thermoregulation 
system. 
Figure 4. NO production from cytokine-induced RAW cells pretreated with A) black cohosh (PureWorld) or B) 23-epi-26-deoxyactein. Data 
are expressed as mean % of cytokine-treated control ± SE.  *P < 0.05 vs cytokine control.30
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Hepatotoxicity
There have been a handful of case reports linking 
black cohosh to liver damage (Levitsky et al. 2005, 
Cohen et al. 2004, Lontos et al. 2003, Whiting et al. 
2002), (reviews in (Thomsen et al. 2004, Huntley, 
2004, Huntley and Ernst, 2003)). Conclusions from 
these case reports were confounded by the lack of 
details reported, for example, dose, source, and 
preparation of black cohosh. For example, in the 
case in which a liver transplant was necessary, the 
woman had been taking 500 mg black cohosh 
extract daily, whereas the generally recommended 
daily dose is 20 or 40 mg (Levitsky et al. 2005). 
In another case report, hepatitis symptoms 
continued four months after discontinuation of 
black cohosh, so the hepatitis is unlikely related to 
the herb (Cohen et al. 2004). Herbs other than black 
cohosh were being ingested by subjects in some 
case reports, including ground ivy which contains 
pugelone, a known liver toxicant (Thomsen et al. 
2004). Using WHO criteria, in which cases are 
categorized as unclassiﬁ  able, unclassiﬁ  ed, unlikely, 
possible, probably, or certain, to evaluate the link 
between hepatic toxicity and black cohosh, of three 
case reports reviewed, two cases were deemed 
unclassiﬁ  ed and one case possible (Huntley and 
Ernst, 2003). Two clinical trials evaluating the 
efﬁ  cacy of black cohosh which measured liver 
enzymes before and after treatment found no 
evidence of change in enzyme levels (Osmers et al. 
2005, Nappi et al. 2005). 
In summary, the literature to date does not 
support a direct estrogenic mechanism of BCE to 
explain its effects, but it may act through systems 
involving neurotransmitters and inflammatory 
pathways. The efﬁ  cacy of BCE is supported by 
many, but not all, clinical trials, and there is little 
evidence of toxicity or severe adverse effects due 
to BCE. Women and clinicians want to know if 
BCE works, how it works, and if it is safe. These 
questions cannot yet be answered with absolute 
conﬁ  dence, but the evidence supports its efﬁ  cacy, 
and to date there is little evidence of toxicity, at 
least short-term. 
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